← ANALYST RATINGS · TIPRANKS
Alnylam Pharma (ALNY): analyst forecast and price target
Analyst consensus
Strong Buy19 Buy4 Hold0 Sell
Ratings of 23 analysts in the last 3 months12-month forecast
Based on 23 price targets given in the last 3 months, the average target is $365, the highest $489, the lowest $253. The average is +57.3% from the last price of $232.
Analyst ratings 27
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $255 → $256+0.4% | Hold | +10.4% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $258 → $260+0.8% | Buy | +12.2% | Upgrade | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $251 → $253+0.8% | Hold | +9.1% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $241 → $242+0.4% | Hold | +4.4% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $250 → $252+0.8% | Hold | +8.7% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | $550 → $354−35.6% | Buy | +52.7% | Reiterated | 14.10.26on TipRanks 19:50 | +4.0%next day +0.2% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $256 → $253−1.2% | Hold | +9.1% | Assigned | 14.10.26on TipRanks 07:05 | +1.4%next day +4.0% | ↗ |
| Eric Joseph★★★★★★★★★★#1258 · hits 52% · avg +11.4% | Citi | $340 → $320−5.9% | Buy | +38.0% | Reiterated | 14.10.26on TipRanks 05:35 | +1.4%next day +4.0% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $450 | Buy | +94.1% | Reiterated | 13.10.26on TipRanks 04:50 | −1.4%next day +1.4% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $300 | Hold | +29.4% | Reiterated | 09.10.26on TipRanks Oct 11 19:06 | +3.0%next day −2.4% · 5 days +1.6% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | — | Buy | — | Assigned | 09.10.26on TipRanks 08:25 | +3.0%next day −2.4% · 5 days +1.6% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $350 → $345−1.4% | Buy | +48.8% | Reiterated | 08.10.26on TipRanks 08:55 | +0.5%next day +3.0% · 5 days +4.5% | ↗ |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $283 → $280−1.1% | Buy | +20.8% | Upgrade | 01.10.26on TipRanks Sep 30 23:05 | — | |
| Olivia Brayer★★★★★★★★★★#9632 · hits 39% · avg −1.2% | Cantor Fitzgerald | $325 | Hold | +40.2% | Reiterated | 30.09.26on TipRanks 09:06 | −2.7%next day −6.5% · 5 days −11.0% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $375 → $369−1.6% | Buy | +59.2% | Assigned | 30.09.26on TipRanks 07:35 | −2.7%next day −6.5% · 5 days −11.0% | ↗ |
| Jeffrey Walch★★★★★★★★★★#5662 · hits 100% · avg +19.5% | Bernstein | $376 | Buy | +62.2% | Reiterated | 25.09.26on TipRanks Sep 26 09:00 | +2.0%next day +0.5% · 5 days −13.9% | ↗ |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $455 | Buy | +96.3% | Reiterated | 21.09.26on TipRanks 06:31 | +0.4%next day +3.0% · 5 days +5.5% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | — | Buy | — | Reiterated | 18.09.26on TipRanks 07:45 | −2.6%next day +0.4% · 5 days +5.6% | ↗ |
| David Lebowitz★★★★★★★★★★#597 · hits 60% · avg +14.2% | Citi | $318 | Buy | +37.2% | Reiterated | 17.09.26on TipRanks Sep 18 08:55 | +1.4%next day −2.6% · 5 days +0.8% | ↗ |
| Joseph Stringer★★★★★★★★★★#293 · hits 48% · avg +24.7% | Needham | $357 | Buy | +54.0% | Reiterated | 17.09.26on TipRanks 14:15 | +1.4%next day −2.6% · 5 days +0.8% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $230 → $260+13.0% | Hold | +12.2% | Reiterated | 08.09.26on TipRanks 06:50 | −1.7%next day −0.3% · 5 days −7.3% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $325 | Buy | +40.3% | Reiterated | 31.08.26on TipRanks 09:15 | +1.8%next day +2.9% · 5 days +8.2% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $489 | Buy | +110.9% | Reiterated | 31.08.26on TipRanks 07:35 | +1.8%next day +2.9% · 5 days +8.2% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $318 | Buy | +37.2% | Reiterated | 31.08.26on TipRanks 07:30 | +1.8%next day +2.9% · 5 days +8.2% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $429 | Buy | +85.0% | Reiterated | 28.08.26on TipRanks Aug 31 09:05 | +0.5%next day +1.8% · 5 days +12.1% | ↗ |
| Unknown Analyst | Wells Fargo | $316 → $256−19.0% | Hold | +10.4% | Assigned | 14.08.26on TipRanks Aug 17 23:05 | +0.9%next day −1.3% · 5 days +4.7% | ↗ |
| Martin Auster★★★★★★★★★★#1128 · hits 51% · avg +16.1% | Raymond James | $468 → $420−10.3% | Buy | +81.2% | Reiterated | 31.07.26on TipRanks 08:40 | −0.7%next day +5.8% · 5 days +3.1% | ↗ |
| Kostas Biliouris★★★★★★★★★★#9060 · hits 41% · avg −0.1% | Oppenheimer | $500 → $350−30.0% | Buy | +51.0% | Reiterated | 31.07.26on TipRanks 08:06 | −0.7%next day +5.8% · 5 days +3.1% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | $482 | Buy | +107.9% | Assigned | 31.07.26on TipRanks 03:46 | −0.7%next day +5.8% · 5 days +3.1% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 30.07.26on TipRanks 12:29 | −30.0%next day −0.7% · 5 days +1.6% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $550 | Buy | +137.2% | Reiterated | 25.06.26on TipRanks Jun 26 08:25 | −0.4%next day +0.1% · 5 days +5.3% | ↗ |
| Keay Nakae★★★★★★★★★★#3914 · hits 40% · avg +3.0% | Chardan Capital | $425 | Buy | +83.3% | Reiterated | 01.05.26on TipRanks Apr 30 22:50 | −4.6%next day +1.0% · 5 days −2.7% | ↗ |
| Mani Foroohar★★★★★★★★★★#11266 · hits 43% · avg −2.1% | Leerink Partners | $370 → $351−5.1% | Hold | +51.4% | Reiterated | 15.12.25on TipRanks 09:30 | −1.4%next day +0.2% · 5 days +3.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Alnylam Pharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $366 at a price of $247 (+48.2%); now: $365 at $232 (+57.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 19 | 24 | 34 | 35 | 29 | 15 |
| Buy | 17 | 14 | 19 | 23 | 24 | 17 |
| Hold | 7 | 6 | 10 | 9 | 9 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.74 (from $0.86 to $2.97). Last quarter: $1.21.
Sales
Next quarter’s sales estimate — $1.4B (from $1.3B to $1.5B). Last quarter: $1.3B.
Best top-analyst consensus in the sector · Healthcare
About Alnylam Pharma
- CEO: Yvonne L. Greenstreet
- Employees: 2,500
- 675 West Kendall Street, Cambridge, MA, 02142, US
- www.alnylam.com
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Nova
Data from the stock’s TipRanks forecast page, read 25 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗